

COAGULOPATHIES AND ALTERATIONS OF HAEMOSTASIS

PUBLICATIONS

- * Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V, Martín-Salces M, Arias-Salgado EG, Pollmar MIR, Sanz RJ, Butta NV. Procoagulant profile in patients with immune thrombocytopenia. *Brit J Haematol*. 2016;175(5):925-34. Article. IF: 5.67; Q1
- * Álvarez-Román MT, Pollmar MIR, Bernardino JI, Lozano ML, Martín-Salces M, Fernández-Bello I, Jiménez-Yuste V, Butta NV. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. *AIDS*. 2016;30(7):1141-2. Letter. IF: 5.003; Q1
- * Auerswald G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Salek SZ. Pain and pain management in haemophilia. *Blood Coagul Fibrin*. 2016;27(8):845-54. Review. IF: 1.367; Q4
- * Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo A, Loures E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruin G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilarino D, Arijia O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo A, Sarmiento L, Inigo B, Nieto MD, Vidal R, Martínez MP, Aguinaco R, Cesar JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borrás N, Vidal F. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. *Thromb Haemostasis*. 2016;115(1):40-50. Article. IF: 5.627; D1
- * de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Hernández-Moreno AL. Coexistence of factor VII deficiency and hereditary spastic paraplegia in two siblings. *Case Rep Hematol*. 2016; 1351873. Article. IF: Not Indexed
- * González-López TJ, Álvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, Pérez-Crespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Núñez M, Olivera P, Martínez-Robles V, Fernández-Rodríguez A, Fuertes-Palacio MA, Fernández-Minano C, de Cabo E, Fisac R, Aguilar C, Báez A, Penarrubia MJ, García-Frade LJ, González-Porrás JR. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. *Eur J Haematol*. 2016;97(3):297-302. Article. IF: 2.653; Q2
- * Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K, Lambert T, Rocino A, Jiménez-Yuste V, Astermark J. Current view and

outcome of ITI therapy - A change over time? *Thromb Res.* 2016;148:38-44. Article. IF: 2.65; Q2

- * Jiménez-Yuste V, Kruse-Jarres R, Rangarajan S, Altisent C. The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders. *Thromb Haemostasis.* 2016;116:S1. Editorial Material. IF: 5.627; D1.
- * Jiménez-Yuste V, Oldenburg J, Rangarajan S, Kurth MH, Bozzo J, Santagostino E. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors. *Haemophilia.* 2016;22(1):E71-4. Letter. IF: 3.569; Q2
- * Jiménez-Yuste V, Oldenburg J, Rangarajan S, Peiró-Jordán R, Santagostino E. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study. *Haemophilia.* 2016;22(6):859-65. Article. IF: 3.569; Q2
- * Kreuz W, Ettingshausen CE, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanska E, Campos M, Benedik-Dolnicar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Salek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. *Haemophilia.* 2016;22(1):87-95. Article. IF: 3.569; Q2
- * López-Fernández MF, Roca CA, Álvarez-Román MT, Hirnyk MIC, Mingot-Castellanos ME, Jiménez-Yuste V, Haro ARC, Pérez-Garrido R, Balbas CS. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. *Thromb Haemostasis.* 2016;115(5):872-95. Article. IF: 5.627; D1
- * Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. *Virus Res.* 2016;213:224-9. Article. IF: 2.628; Q3
- * Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Altisent-Roca C, Canaro-Hirnyk MI, Jiménez-Yuste V, Cid-Haro AR, Pérez-Garrido R, Sedano-Balbás C. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. *Eur J Haematol.* 2016;96(5):461-74. Review. IF: 2.653; Q2
- * Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petes B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, Prondzinski MV, Altisent C, Castaman G, Yamamoto K, Álvarez-Román MT, Voigt C, Blackman N, Jacobs I. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. *Blood.* 2016;127(14):1761-9. Article. IF: 13.164; D1

- * Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. *Thromb Haemostasis*. 2016;116:S10-S17. Article. IF: 5.627; D1
- * Wang M, Álvarez-Román MT, Chowdary P, Quon DV, Schafer K. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX FC fusion protein for the treatment of active patients: a literature review and case reports. *Blood Coagul Fibrin*. 2016;27(7):737-44. Review. IF: 1.367; Q4